Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bacillus licheniformis in decompensated cirrhosis
ChiCTR1800014600Phase 4Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Feb 2018
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of bacillus licheniformis in Cirrhosis (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Intestinal changes in the environment. Planned start Feb 2018; status: not yet recruiting.
02
Drugs
bacillus licheniformis
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on ChiCTR1800014600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014600.